Innocan Pharma's Compassionate Care Treatment for Dogs

A Case Report Published in Frontiers in Veterinary Science

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the publication of a case report regarding its compassionate care liposomal-CBD formulation (Innocan's LPT platform) (the "**Treatment**"). The Treatment was administered to a 14-year-old dog suffering from severe cervical pain, hip and elbow osteoarthritis and testicular neoplasia. It was reported that the Treatment resulted in decreased pain and improved mobility. The journal, *Frontiers in Veterinary Science*, is a global, peer-reviewed, open access publication that bridges animal and human health, brings a comparative approach to medical and surgical challenges, and advances innovative biotechnology and therapy.

The Treatment involved a novel cannabidiol (CBD) analgesic, administered to a dog that was cachectic and had hip and elbow osteoarthritis and severe neck pain in addition to a testicular neoplasia. The dog had been previously unsuccessfully treated with a canine osteoarthritic supplement, non-steroidal anti-inflammatory drugs and gabapentin. Therefore, an addition of Innocan's LPT liposomal CBD injectable formulation was administered subcutaneously and the dog was monitored via: (i) an activity monitoring collar (PetPace); (ii) owner wellbeing questionnaire; (iii) a pain interactive visual analogue scale (iVAS); (iv) blood work and CBD plasma concentrations. One week from the Liposomal-CBD administration and for up to three weeks following the Treatment, the dog had improved and the owner-provided pain scores were reduced from 21 to 10 (on a scale of 40) and iVAS pain scores were reduced from 10 to seven (on a scale of 10). Additionally, collar activity scores were increased from approximately five to 25 (Figure 1). CBD was quantified in the dog's plasma for at least 28 days after the Treatment.



FIGURE 1 | Daily average activity scores collected via an activity monitoring collar (PetPace) from a 14-year-old dog suffering from bilateral hip and elbow osteoarthritis and severe neck pain, before and after liposomal cannabidiol (CBD) subcutaneous injection. X-axis represents days before (negative) and after (positive) liposomal CBD injection on day 0.

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/122083_05ff4cdd34b1b9aa_002full.jpg

This case report showed that subcutaneous administration of liposomal CBD provides high exposure in terms of AUC (Area Under the Curve), with CBD plasma concentrations maintained for at least 28 days after Treatment. The pharmacokinetic data combined with the related efficacy data suggest that treatment with liposomal-CBD in this case may be an effective and attractive additional treatment as part

of multimodal pain management in dogs suffering from chronic pain. This formulation can be an alternative route to oral CBD administration in cases where owner compliance, palatability and/or bioavailability are low. Further investigations of this formulation are of interest.

Frontiers | A Case Report of Subcutaneously Injected Liposomal Cannabidiol Formulation Used as a Compassion Therapy for Pain Management in a Dog | Veterinary Science (frontiersin.org).

"I would like to thank our most brilliant team of scientists associated with our Liposome technology labs in Jerusalem: Ahuva Cern, Daniel Zilbersheid, Atara Hod and Prof. Barenholz," said Iris Bincovich, CEO of Innocan, "I am thrilled to see one of the world's most renowned publications covering our achievement from the Jerusalem labs that may serve as evidence to the efficacy of our formulations and drug delivery systems."

Innocan's relationship with The Hebrew University

Innocan Pharma Ltd., a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company ("**Yissum**"), the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development initiative is led by Professor Chezy Barenholz, head of the Membrane and Liposome Research Department at The Hebrew University, which is the inventor of over fifty-five patent families, two of which underlie Doxil®, an FDA-approved drug for breast cancer treatment. This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. A patent was filed covering this technology on October 7, 2019.

About Innocan

Innocan Pharma is a pharmaceutical technology company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.

Innocan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administered by injection. Innocan Israel plans, together with Professor Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Pharma Ltd. each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

INNOCAN
PHARMA

To view the source version of this press release, please visit
https://www.newsfilecorp.com/release/122083